Puneeth Iyengar on the Benefits of Hypofractionated Radiation Therapy in Lung Cancer

A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Serial CTRS, an AI-powered tool, has been granted FDA breakthrough device designation for classifying patients with NSCLC.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.

Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy.